SINT1A

Supplementation with B. infantis to mitigate Type 1 Diabetes Autoimmunity

The SINT1A study is a randomized, placebo-controlled, double-blind, primary prevention study designed to demonstrate the potential benefits of Bifidobacterium infantis in preventing islet autoimmunity and type 1 diabetes in genetically high-risk children. The intervention involves the daily administration of the probiotic or a placebo given to infants from the age of 7 days to 6 weeks until they reach 12 months. The SINT1A study is conducted in five countries: Germany, UK, Poland, Belgium and Sweden.

Enrollment Completed

As of early 2024, enrollment has been completed with a total of 1149 infants participating in the study. In addition to the primary focus on islet autoimmunity and type 1 diabetes, the study also examines other health outcomes such as celiac autoimmunity, respiratory infections, allergy, antibody response to vaccines, and alterations in the gut microbiome. This broad approach allows for a more comprehensive understanding of the probiotic’s effects on various aspects of health.